Risk of contralateral breast and other cancers in patients with invasive lobular breast cancer.

Authors

null

Grace Mei Yee Choong

Mayo Clinic, Rochester, MN

Grace Mei Yee Choong , Samuel T. Savitz , Karthik Giridhar , Tufia C. Haddad , Kathryn Jean Ruddy , Judy Caroline Boughey , Matthew P. Goetz , Fergus Couch , Siddhartha Yadav

Organizations

Mayo Clinic, Rochester, MN, Mayo Clinic Kern Center, Rochester, MN, Department of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Research Funding

Other

Background: Women with early-stage breast cancer (BCa) are living longer, and survivorship issues including second primary cancers (SPCs) are therefore increasingly important. This study seeks to determine the risk of SPCs, including contralateral breast cancer (CBCa), in women with early-stage invasive lobular carcinoma (ILC). Methods: The study population consisted of women with BCa diagnosis between 2000-2018 within the NCI Surveillance, Epidemiology, and End Results (SEER v 3.2.9) registry and between 2000-2021 in the Mayo Clinic Cancer Registry. In the SEER registry, the standardized incidence ratios (SIR) for SPCs were estimated for adult women with histologically confirmed early stage (I-III) ILC compared to the development of any primary cancer in the general population. For reference, SIRs for SPCs for a similar patient population with invasive ductal carcinoma (IDC) of the breast were also estimated. For comparison of CBCa between ILC and IDC, follow up records from the Mayo Clinic Cancer Registry were evaluated among adult women who underwent lumpectomy or unilateral mastectomy for early stage ILC or IDC. A multivariable Cox proportional hazards regression was performed to compare the risk of CBCa between ILC and IDC while adjusting for the age at diagnosis, race/ethnicity and estrogen receptor status of the primary tumor. Results: An increased incidence (p<0.05) of any SPCs and second BCa was noted for both ILC and IDC compared to the expected rate of primary cancer in the general population (Table). Interestingly, women with ILC were observed to have a significantly increased incidence of subsequent gastric cancer which was not seen for women with IDC. An SIR >1.5 was noted for subsequent risk of sarcoma, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) for both ILC and IDC (Table). In the Mayo Clinic Cancer Registry of 2,218 women with ILC and 14,629 women with IDC meeting the inclusion criteria, the 5-year risk of CBCa was 2.6% and 1.5% (log rank statistic p-value =0.001) for ILC and IDC respectively. A significantly increased risk of CBCa was noted in women with ILC (Hazard Ratio 1.82, 95% CI 1.34-2.47, p<0.001) compared to women with IDC in the multivariable analysis. Conclusions: Women with ILC may have an increased risk of SPC and second BCa compared to the risk of any primary cancer in the general population. The increased incidence of gastric cancer and the higher risk of CBCa in ILC survivors compared to women with IDC is intriguing and needs to be investigated further including evaluation of the role of germline genetic factors.

SIR for SPC in IDC and ILC in the SEER dataset.


ILC

SIR (95% CI)
IDC

SIR (95% CI)
All cancers
1.09 (1.07-1.12)*
1.16 (1.15-1.17)*
Breast
1.36 (1.31-1.42)*
1.39 (1.37-1.41)*
Gastric
1.67 (1.40-1.99)*
1.03 (0.95-1.11)
Sarcoma
1.64 (1.22-2.15)*
1.60 (1.45-1.76)*
MDS
1.84 (1.54-2.18)*
1.82 (1.71-1.91)*
AML
1.97 (1.59-2.41)*
2.08 (1.94-2.24)*

*p value < 0.05

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 555)

DOI

10.1200/JCO.2022.40.16_suppl.555

Abstract #

555

Poster Bd #

327

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Correlation of unobserved incidence of cancer in earlier stages with the observed incidence.

First Author: Jagpreet Chhatwal

First Author: Amina Dhahri

Abstract

2023 ASCO Annual Meeting

Associations between micro-geographic social vulnerability and disparities in cancer incidence.

First Author: Ismail Aijazuddin

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Trends in incidence and survival of early-stage pancreatic ductal adenocarcinoma in the United States.

First Author: Gerardo Perrotta